RCUSArcus Biosciences, Inc.
Price
+97%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality strong, nothing alarming, growth fading, the market undecided.
We are a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clinical-stage molecules to come from our inflammation and autoimmune disease programs. Our vision is to leverage our internal small-molecule discovery capabilities to create, develop and commercialize highly differentiated therapies that can have a meaningful impact on patients.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Arcus Biosciences, Inc. (RCUS) reported revenue of $41M in Q2 2026 (quarter ended Jun 30, 2026), down 74% from the same quarter a year earlier. That came with net loss of $91M. For the full year FY2025, revenue was $247M (−4.3% year on year) and net income −$353M. Its largest product in Q2 2026 was Access Rights at $21M, 57% of the disclosed total, well ahead of License And Development Services at 22%. The next results filing is expected around Oct 27, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update.Earnings release · press release
- May 5, 2026Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update.Earnings release · press release
- Apr 20, 2026STAR-121 Update. On April 20, 2026, Arcus Biosciences, Inc. (the “Company”) announced the discontinuation of the Phase 3 STAR-121 study, which is being conducted in collaboration with Gilead Sciences, Inc. (“Gilead”), due to futility.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $37.0MThe company’s own SEC segment disclosure.
- Access Rights$21.0M57%
- License And Development Services$8.0M22%
- License$4.0M11%
- RD Services$4.0M11%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.